Exploring the synergistic effects of topoisomerase I inhibitors and immunotherapy in overcoming treatment resistance
In the battle against melanoma, one of the most aggressive forms of skin cancer, science has been writing a remarkable success story over the past decade. For patients with advanced, unresectable melanoma, the outlook was once grim—with a median survival of just 6-9 months before 2011 5 .
East Asian patients often experience less favorable outcomes than Caucasian populations
Then came immunotherapy, a revolutionary approach that harnesses the body's own immune system to fight cancer cells. Drugs known as immune checkpoint inhibitors (such as anti-PD-1 and anti-CTLA-4 antibodies) have since transformed melanoma treatment, pushing median survival to nearly six years for some patients with stage IV disease 5 .
Despite these advances, a stubborn problem remains: not all patients benefit equally from immunotherapy. Response rates to anti-PD-1 antibodies—the current backbone of melanoma treatment—vary significantly, with East Asian patients often experiencing less favorable outcomes than Caucasian populations 1 .
The reality is that many melanoma patients either don't respond initially to immunotherapy or develop resistance over time 1 8 . For those with BRAF wild-type melanoma that has stopped responding to anti-PD-1 therapy, no standard treatment options currently exist 1 .
This pressing clinical challenge has prompted scientists to investigate innovative combination approaches that can overcome resistance and make tumors more vulnerable to immune attack. One of the most promising strategies emerges from an unexpected direction: combining immunotherapy with a class of DNA-targeting drugs called topoisomerase I inhibitors 2 .
To understand how topoisomerase inhibitors work, we first need to appreciate a fundamental challenge our cells face: DNA entanglement. Imagine trying to separate two strands of a rope that have been twisted together thousands of times—the tension would make them virtually impossible to pull apart. This is exactly the problem our cells encounter during DNA replication and transcription.
Every time a cell divides—a process that happens millions of times daily in our bodies—it must precisely copy all 3 billion base pairs of DNA. The double-helix structure of DNA naturally becomes overwound and tangled during this process.
These remarkable molecular machines act as "genetic scissors," creating temporary breaks in the DNA strands to relax the tension and then seamlessly resealing the cuts once the strands have unwound 3 .
Makes single-strand cuts in DNA, allowing controlled rotation and relaxation of the double helix 3 .
Makes double-strand breaks, particularly important for untangling separate DNA molecules 3 .
Cancer cells, which divide uncontrollably, are especially dependent on topoisomerase activity. This dependency makes them vulnerable to topoisomerase inhibitors—drugs that sabotage these essential enzymes. When these drugs block topoisomerase function, cancer cells become entangled in their own DNA, leading to lethal DNA breaks and cell death 3 .
In 2018, a pivotal study published in the Journal of the National Cancer Institute revealed a surprising synergy between topoisomerase inhibitors and cancer immunotherapy 2 6 . The research team, led by scientists at the National Cancer Institute, asked a critical question: Could certain drugs make melanoma cells more susceptible to T-cell-mediated killing?
The team screened 850 different compounds against patient-derived melanoma cell lines along with their matching tumor-infiltrating lymphocytes (TILs)—the immune cells that naturally try to attack tumors 2 .
Using RNA interference, overexpression studies, and gene expression analysis, they identified the specific molecular pathway responsible for the enhanced immune killing 2 .
They tested the most promising combination in a syngeneic mouse model (mice with functioning immune systems), treating tumor-bearing animals with a clinically relevant topoisomerase inhibitor (liposomal irinotecan, also known as MM-398) combined with anti-PD-L1 or anti-PD1 antibodies 2 .
The screening process used an innovative metric called a "comboscore" to quantify how effectively each drug enhanced T-cell-mediated killing of melanoma cells. A comboscore greater than 1 indicated enhanced immune activity against the tumor 2 .
The findings were compelling. Three topoisomerase I inhibitors—topotecan hydrochloride, camptothecin, and irinotecan hydrochloride trihydrate—emerged as top hits from the initial screening, significantly increasing the melanoma cells' susceptibility to T-cell attack 2 .
| Compound Class | Example Drugs | Comboscore | Effect on T-cell Killing |
|---|---|---|---|
| Topoisomerase I Inhibitors | Topotecan, Camptothecin, Irinotecan | >1.5 | Dramatically increased |
| Other drug classes | Various compounds from library | <1.5 | Minimal or no enhancement |
Even more impressive were the in vivo results. Mice treated with the combination of a topoisomerase I inhibitor (MM-398) and immune checkpoint blockers showed significantly better tumor control and prolonged survival compared to those receiving either treatment alone 2 .
| Treatment Group | Tumor Control | Survival Benefit | Statistical Significance |
|---|---|---|---|
| Control | Baseline | Baseline | - |
| MM-398 alone | Moderate improvement | Minimal | P > 0.05 |
| α-PD-L1 alone | Moderate improvement | Minimal | P > 0.05 |
| MM-398 + α-PD-L1 | Dramatic improvement | Significant | P = 0.002 |
| MM-398 + α-PD1 | Dramatic improvement | Significant | P = 0.008 |
The researchers didn't stop at simply observing this effect—they dug deeper to understand the molecular mechanism. Through elegant experiments, they identified a protein called TP53INP1 as the crucial mediator. When they overexpressed this protein in melanoma cells, the cells became more vulnerable to T-cell killing. Conversely, when they knocked down TP53INP1 expression, the enhancement effect of topoisomerase inhibitors disappeared 2 .
This groundbreaking research was made possible by specialized reagents and experimental tools that allowed precise investigation of the interaction between topoisomerase inhibitors and the immune system.
Provided authentic human tumor models for screening, maintaining critical tumor characteristics absent in conventional lab-grown cells.
Enabled assessment of tumor-specific immune responses, allowing testing of immune recognition against the actual patient's tumor.
Quantified tumor cell death by detecting apoptosis, providing precise measurement of T-cell killing capacity.
Knocked down specific genes to test their function, identifying TP53INP1 as essential for the combination effect.
Allowed in vivo testing in immunologically intact animals, providing preclinical data on tumor control and survival.
The implications of this research extend far beyond the laboratory. By demonstrating that topoisomerase I inhibitors can significantly enhance the effectiveness of T-cell-based immunotherapy, this work provides a rational scientific foundation for new combination treatment strategies 2 . This approach represents a paradigm shift in our thinking about chemotherapy—rather than being merely cytotoxic, certain chemotherapeutic drugs can play an immunomodulatory role that enhances the body's natural defenses against cancer.
"This discovery comes at a crucial time in melanoma treatment. While newer immunotherapies like anti-LAG-3 antibodies (relatlimab) have continued to push the field forward since their approval in 2022 5 , the fundamental challenge of resistance remains."
The topoisomerase inhibitor approach offers a promising strategy to overcome this resistance by addressing the problem from multiple angles—directly damaging tumor DNA while simultaneously making the cancer cells more "visible" and vulnerable to immune attack.
Topoisomerase inhibitors can increase expression of melanocytic antigens on tumor cells
The potential of this combination strategy is further supported by independent research showing that certain topoisomerase inhibitors can increase expression of melanocytic antigens on tumor cells, essentially providing the immune system with better targets to recognize and attack 4 .
As we look to the future, the path forward involves validating these findings in clinical trials and determining which specific patient populations will benefit most from this approach. The growing market for topoisomerase I inhibitors—projected to reach $6.95 billion by 2029—reflects increasing investment and development in this drug class 7 , potentially creating more opportunities for combination studies.
For patients facing melanoma that has stopped responding to available immunotherapies, the marriage of DNA-targeting drugs with immune activation represents a beacon of hope—a demonstration that even when cancer devises escape routes, scientific ingenuity can find new ways to corner it.
References will be added here in the appropriate format.